FDA approves Nuvo/Galderma's Pliaglis
This article was originally published in Scrip
The US FDA has approved a supplemental new drug application for Pliaglis (lidocaine/tetracaine), Nuvo Research and Galderma's topical anaesthetic cream, having changed its mind since April when it issued a complete response letter for the drug.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.